CA2696807C - Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease - Google Patents

Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease Download PDF

Info

Publication number
CA2696807C
CA2696807C CA2696807A CA2696807A CA2696807C CA 2696807 C CA2696807 C CA 2696807C CA 2696807 A CA2696807 A CA 2696807A CA 2696807 A CA2696807 A CA 2696807A CA 2696807 C CA2696807 C CA 2696807C
Authority
CA
Canada
Prior art keywords
compound
formula
another embodiment
leukemia
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2696807A
Other languages
English (en)
French (fr)
Other versions
CA2696807A1 (en
Inventor
Joyce K. James
Traci L. Savall
Shawn R. Eichelberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambit Bioscience Corp
Original Assignee
Ambit Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Bioscience Corp filed Critical Ambit Bioscience Corp
Publication of CA2696807A1 publication Critical patent/CA2696807A1/en
Application granted granted Critical
Publication of CA2696807C publication Critical patent/CA2696807C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2696807A 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease Active CA2696807C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US258307P 2007-11-08 2007-11-08
US61/002,583 2007-11-08
US580307P 2007-12-07 2007-12-07
US61/005,803 2007-12-07
US9867608P 2008-09-19 2008-09-19
US61/098,676 2008-09-19
US11206008P 2008-11-06 2008-11-06
US61/112,060 2008-11-06
PCT/US2008/012539 WO2009061446A1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Publications (2)

Publication Number Publication Date
CA2696807A1 CA2696807A1 (en) 2009-05-14
CA2696807C true CA2696807C (en) 2017-11-28

Family

ID=40262072

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2696807A Active CA2696807C (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Country Status (18)

Country Link
US (1) US7968543B2 (enExample)
EP (2) EP2596795A1 (enExample)
JP (2) JP5645667B2 (enExample)
KR (2) KR20150105494A (enExample)
CN (1) CN101835472A (enExample)
AR (1) AR069244A1 (enExample)
AU (1) AU2008325141B2 (enExample)
CA (1) CA2696807C (enExample)
CY (1) CY1114853T1 (enExample)
DK (1) DK2205244T3 (enExample)
ES (1) ES2436266T3 (enExample)
HR (1) HRP20131083T1 (enExample)
MX (1) MX2010002396A (enExample)
PL (1) PL2205244T3 (enExample)
PT (1) PT2205244E (enExample)
SI (1) SI2205244T1 (enExample)
TW (1) TW200924756A (enExample)
WO (1) WO2009061446A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101449057B1 (ko) 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
BRPI0816904B8 (pt) 2007-09-19 2021-12-07 Ambit Biosciences Corp Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
CN104447801A (zh) 2009-11-05 2015-03-25 埃姆比特生物科学公司 用于制备咪唑并[2,1-b][1,3]苯并噻唑衍生物的方法
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513259B (zh) * 2013-09-26 2017-06-16 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
BR112017002001B1 (pt) 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
KR102769649B1 (ko) 2014-12-22 2025-02-19 젠자임 코포레이션 포유류 세포의 배양 방법
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
US10278979B2 (en) * 2015-03-11 2019-05-07 Riken Therapeutic agent for intractable leukemia
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113966331B (zh) * 2020-03-11 2024-04-12 暨南大学 含脲结构的三芳环化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233903A (en) * 1880-11-02 Velocipede
US233906A (en) * 1880-11-02 Combined stirrer and thermometer
US994635A (en) * 1911-01-10 1911-06-06 Harry C Buhoup Car-truck.
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
KR101449057B1 (ko) 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
BRPI0816904B8 (pt) * 2007-09-19 2021-12-07 Ambit Biosciences Corp Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida

Also Published As

Publication number Publication date
JP5645667B2 (ja) 2014-12-24
CN101835472A (zh) 2010-09-15
PL2205244T3 (pl) 2014-01-31
EP2205244B1 (en) 2013-08-21
TW200924756A (en) 2009-06-16
AU2008325141B2 (en) 2014-03-20
EP2596795A1 (en) 2013-05-29
US20090123418A1 (en) 2009-05-14
SI2205244T1 (sl) 2013-12-31
ES2436266T3 (es) 2013-12-30
KR20100075853A (ko) 2010-07-05
CA2696807A1 (en) 2009-05-14
WO2009061446A1 (en) 2009-05-14
MX2010002396A (es) 2010-04-01
AR069244A1 (es) 2010-01-06
KR101578481B1 (ko) 2015-12-17
US7968543B2 (en) 2011-06-28
HRP20131083T1 (hr) 2013-12-20
JP2011503063A (ja) 2011-01-27
CY1114853T1 (el) 2016-12-14
PT2205244E (pt) 2013-11-26
EP2205244A1 (en) 2010-07-14
DK2205244T3 (da) 2013-11-25
KR20150105494A (ko) 2015-09-16
AU2008325141A1 (en) 2009-05-14
JP2014221765A (ja) 2014-11-27

Similar Documents

Publication Publication Date Title
US7968543B2 (en) Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
US9555040B2 (en) Methods of treating proliferative diseases
JP6033678B2 (ja) 併用療法を用いた治療方法
TW201936179A (zh) Ｈｓｐ９０－靶定之共軛物及其調配物
HK1250645A1 (zh) 取代的2，3-二氢咪唑并[1，2-c]喹唑啉类化合物的用途
KR101760657B1 (ko) 약제학적 병용물
CN104168908A (zh) 罗米地新制剂及其用途
EP3340969B1 (en) Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
TW202440116A (zh) 組合療法
CN119233821A (zh) Pi3k抑制剂与pd-1抑制剂的组合疗法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131023

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250930